CURRENT DERMATOLOGY CLINICAL TRIALS

ACELYRIN:
A randomized, double-blind, placebo-controlled, multicenter, phase 3 study to evaluate the efficacy and safety of Izokibep in subjects with moderate to severe Hidradenititis Suppurativa (HS). 

Inclusion Criteria:

• Subject must be ≥ 18 (or the legal age of consent in the jurisdiction in which the study is taking place) and ≤ 75 years of age, at the time of signing the informed consent.

• Diagnosis of HS for ≥ 6 months prior to first dose of study drug.​